From the Journals

Low-carb diets boost diabetes remission rates, at least short term


 

VLCDs: Adherence Is key

Finally, the team looked at weight loss achieved with VLCDs.

VLCDs were less effective for weight loss at 6 months than less restrictive LCDs. However, this effect was explained by diet adherence, the researchers noted.

Restricting the analysis to “credible” studies, VLCDs were associated with a larger “clinically important” weight-loss versus control diets when patients were highly adherent to the diet, at a mean reduction of 4.47 kg (9.9 lb) versus a mean increase of 0.55 kg (1.2 lb) among patients who were less adherent.

The team noted that their review has a number of limitations, not least of which is the definition of diabetes remission used, which “is the subject of considerable debate,” as well as the safety concerns raised over LCDs.

Given the latter concerns, “clinicians might consider short-term LCDs for management of type 2 diabetes, while actively monitoring and adjusting diabetes medication as needed,” they concluded.

This study was funded in part by Texas A&M University. One coauthor reported receiving funding from Texas A&M AgriLife Research for a separate research project. Dr. Brinkworth is author of the book “The CSIRO Low Carb Diet,” but does not receive financial royalties or funds either directly or indirectly.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

New study pinpoints how Mediterranean diet reduces diabetes risk
Federal Practitioner
Noninvasive, low-cost CGM for type 2 diabetes coming in U.S. and EU
Federal Practitioner
Diabetic retinopathy may predict greater risk of COVID-19 severity
Federal Practitioner
Burnt Out ? The Phenomenon of Type 2 Diabetes Mellitus in End-Stage Renal Disease
Federal Practitioner
ADA 2021 standards address financial hardship in diabetes
Federal Practitioner
FDA okays first generic injected glucagon for hypoglycemia
Federal Practitioner
Large study links brown fat with lower rates of cardiometabolic disease
Federal Practitioner
Pressure builds on CDC to prioritize both diabetes types for vaccine
Federal Practitioner
Biomarker HF risk score envisioned as SGLT2 inhibitor lodestar in diabetes
Federal Practitioner
Further warning on SGLT2 inhibitor use and DKA risk in COVID-19
Federal Practitioner